Sierra Oncology, Inc. (SRRA) Reaches $3.25 After 4.00% Down Move; Cirrus Logic (CRUS) SI Increased By 0.86%

January 14, 2018 - By wolcottdaily

The stock of Sierra Oncology, Inc. (NASDAQ:SRRA) is a huge mover today! The stock decreased 2.99% or $0.1 during the last trading session, reaching $3.25. About 810,392 shares traded or 23.66% up from the average. Sierra Oncology, Inc. (NASDAQ:SRRA) has declined 77.65% since January 14, 2017 and is downtrending. It has underperformed by 94.35% the S&P500.The move comes after 9 months negative chart setup for the $169.96M company. It was reported on Jan, 14 by Barchart.com. We have $3.12 PT which if reached, will make NASDAQ:SRRA worth $6.80M less.

Cirrus Logic Incorporated (NASDAQ:CRUS) had an increase of 0.86% in short interest. CRUS’s SI was 5.14 million shares in January as released by FINRA. Its up 0.86% from 5.09 million shares previously. With 715,300 avg volume, 7 days are for Cirrus Logic Incorporated (NASDAQ:CRUS)’s short sellers to cover CRUS’s short positions. The stock increased 0.96% or $0.5 during the last trading session, reaching $52.84. About 531,770 shares traded. Cirrus Logic, Inc. (NASDAQ:CRUS) has risen 97.50% since January 14, 2017 and is uptrending. It has outperformed by 80.80% the S&P500.

Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response therapeutics for the treatment of patients with cancer in the United States and internationally. The company has market cap of $169.96 million. The companyÂ’s lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. It currently has negative earnings. It also engages in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in preclinical development stage.

Analysts await Sierra Oncology, Inc. (NASDAQ:SRRA) to report earnings on March, 1. They expect $-0.20 EPS, up 33.33% or $0.10 from last year’s $-0.3 per share. After $-0.19 actual EPS reported by Sierra Oncology, Inc. for the previous quarter, Wall Street now forecasts 5.26% negative EPS growth.

Cirrus Logic, Inc., a fabless semiconductor company, develops, makes, and markets analog and mixed-signal integrated circuits for a range of consumer and industrial markets. The company has market cap of $3.36 billion. The firm offers portable and non-portable audio, and other products. It has a 12.96 P/E ratio. The Company’s products include analog and mixed-signal audio converters, and digital signal processing products for mobile applications; codecs-chips that integrate analog-to-digital converters and digital-to-analog converters into a single IC; smart codecs, a codec with digital signal processer; amplifiers; micro-electromechanical systems microphones; digital interface products; and standalone digital signal processors.

Among 15 analysts covering Cirrus Logic (NASDAQ:CRUS), 10 have Buy rating, 2 Sell and 3 Hold. Therefore 67% are positive. Cirrus Logic had 40 analyst reports since July 23, 2015 according to SRatingsIntel. The stock of Cirrus Logic, Inc. (NASDAQ:CRUS) earned “Buy” rating by Stifel Nicolaus on Friday, October 28. The company was maintained on Wednesday, August 2 by Stifel Nicolaus. On Thursday, August 31 the stock rating was maintained by KeyBanc Capital Markets with “Buy”. The company was maintained on Thursday, September 8 by Stifel Nicolaus. The company was upgraded on Friday, January 8 by Pacific Crest. KeyBanc Capital Markets downgraded the shares of CRUS in report on Monday, January 8 to “Sector Weight” rating. The rating was maintained by Needham on Thursday, August 3 with “Buy”. KeyBanc Capital Markets maintained the shares of CRUS in report on Thursday, November 16 with “Buy” rating. The stock of Cirrus Logic, Inc. (NASDAQ:CRUS) has “Buy” rating given on Tuesday, June 21 by Canaccord Genuity. Needham maintained it with “Buy” rating and $80.0 target in Friday, November 3 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>